PHILADELPHIA, PA — Armada Acquisition Corp. III (Nasdaq: AACI) has agreed to merge with Brains Bioceutical Corp. in a transaction valuing the pharmaceutical manufacturer at approximately $750 million before the merger, providing a potential Nasdaq listing to support expansion of its cannabinoid drug manufacturing and development operations.
The proposed business combination would create Brains Therapeutics Corp., with shares expected to trade on the Nasdaq under the ticker symbol BAPI. The companies expect to complete the transaction in the second quarter of 2027, subject to shareholder, regulatory and stock exchange approvals.
Brains’ existing shareholders are expected to retain their entire equity interests in the combined company, according to the merger agreement. Both companies’ boards unanimously approved the transaction.
The deal would bring a pharmaceutical manufacturer with established European production facilities and a portfolio of experimental medicines into the public markets through Armada III, a special purpose acquisition company.
Brains operates an EU-GMP pharmaceutical manufacturing platform through its wholly owned subsidiary, BSPG Laboratories Limited, producing active pharmaceutical ingredients used in regulated healthcare markets.
Its manufacturing and development operations include cannabidiol (CBD), delta-9 tetrahydrocannabinol (THC), delta-8 THC, cannabinol (CBN) and cannabigerol (CBG), along with drug intermediates and finished medical products.
The company supplies pharmaceutical-grade ingredients to customers involved in clinical research and commercial drug production. It also serves the supplement, beverage and personal care industries through branded and private-label products.
Brains said its commercial relationships include major international pharmaceutical companies, including a large South American drug manufacturer and a global generic pharmaceutical producer.
The company’s development strategy combines ingredient manufacturing with proprietary drug programs, licensing arrangements and research partnerships.
Among its more advanced assets is an extended-release methazolamide treatment for glaucoma, for which Brains holds global commercial rights.
A pivotal bioequivalence study conducted under a U.S. Food and Drug Administration Special Protocol Assessment found that the once-daily extended-release formulation was bioequivalent to twice-daily immediate-release methazolamide.
The company is pursuing a potential commercial launch, contingent on filing and obtaining FDA approval of a marketing application and completing additional development milestones.
Brains also supplies clinical trial material for a cannabinoid-based treatment being investigated for opioid use disorder.
The program has received $18 million in National Institutes of Health funding and is undergoing a Phase 3 randomized controlled trial involving approximately 450 participants across seven research sites.
Brains holds an exclusive option to negotiate licensing rights to the program, rather than an existing commercial license.
Additional development programs include a proprietary oral capsule formulation for epilepsy and an internal research opportunity involving sleep disorders.
The company is also pursuing cannabinoid-based medicines and over-the-counter products for companion and performance animals.
Rick Brar, chairman and chief executive officer of Brains Bioceutical, said the proposed listing would support the company’s transition from an established pharmaceutical manufacturing operation toward a broader drug development business.
“We believe becoming a publicly traded company will provide Brains with the capital and market visibility to accelerate the next phase of our development,” Brar said.
The transaction would give Brains access to the public equity markets as it pursues pharmaceutical manufacturing, product development and commercialization opportunities.
Armada III Chairman and Chief Executive Officer Stephen Herbert said the acquisition company selected Brains based on its technology, potential market and management capabilities.
The transaction remains subject to approval by shareholders of both companies, effectiveness of a registration statement with the Securities and Exchange Commission, Nasdaq listing approval and other customary closing conditions.
Armada III’s sponsor and certain Brains shareholders have entered into support and lock-up agreements associated with the proposed merger.
Brookline Capital Markets, a division of Arcadia Securities, and Cohen & Company Capital Markets are serving as joint financial and capital markets advisers to Armada III.
Alvarez & Marsal is providing commercial, tax and operational due diligence services.
Morgan, Lewis & Bockius and Stikeman Elliott are advising Armada III on legal matters, while Borden Ladner Gervais, Origin Law Corporation and Lucosky Brookman are serving as legal advisers to Brains.
Additional transaction details, including the merger agreement and an investor presentation, will be included in a Form 8-K filing with the SEC.
The companies also intend to file a Form F-4 registration statement containing a proxy statement and prospectus for the proposed combination. Shareholders will receive voting materials after the registration statement becomes effective.
The transaction has not been approved by the SEC or state securities regulators.
Investors can access regulatory filings and related transaction documents through the SEC’s website at www.sec.gov.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.
